Lilly signs licensing deal with Mediar for IPF drug
Eli Lilly (NYSE:LLY) has entered into a licensing agreement with Mediar Therapeutics to advance Mediar's drug MTX-463 into ...
GlobalData on MSN1d
Mediar Therapeutics signs licensing deal with Eli Lilly for IPF treatment
Mediar Therapeutics has entered a global licensing agreement with Eli Lilly and Company to progress the human immunoglobulin ...
BioSpace4d
Lilly Makes $780M+ IPF Play with Mediar Partnership
Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early ...
FierceBiotech4d
Eli Lilly pushes into pulmonary fibrosis with $99M deal for Mediar's midphase prospect
Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in ...
The Pharma Letter1d
Mediar Therapeutics inks IPF deal with Lilly
US fibrosis-focused drug developer Mediar Therapeutics has entered into global licensing agreement with US pharma major Eli ...
Medindia5d
Inspira™ Preparing Production in Response to Spread of Respiratory Virus in China
(Nasdaq: IINN) (Nasdaq: IINNW) ("Inspira" or the "Company"), a leader in life-support technology innovation, announced today that it is preparing for a potential production ramp-up of its INSPIRA™ ...
Contract Pharma4d
Mediar, Lilly Enter Global Licensing Agreement for WISP1 Antibody
A Phase 2 trial of MTX-463 in idiopathic pulmonary fibrosis expected in 1H 2025.
BioPharma Dive4d
Pfizer’s PD-1 drug succeeds; AbbVie writes down $3.5B in Cerevel assets
Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma ...